PDCD1 and non-small cell lung carcinoma: Previous analyses have found a slightly more benefit but a lower rate of immune-related adverse events from anti-PD-1 inhibitors than from anti-PD-L1 inhibitors [56,57], suggesting a preferred choice of ICIs for NSCLC patients.